	FAX RECEIVED OCT 1 (- 2002	PATENT Docket No. GC527C3 SN 09/768,080	
	GROUP 1600 FAX COVER SHEET	Urgent Confidential Action Required Reply Requeste	
TO:	Art Unit 1644	For Your Info.	
LOCATION:	USPTO		
Fax No.:	(703) 872-9306, (Before Final Facsimile No.)		
FROM:	Carol See for Kamrin T. MacKnight		
LOCATION:	GENENCOR INTERNATIONAL, IN Legal Department 925 Page Mill Road Palo Alto, CA 94304-1013 Tel: 650-846-7549 Fax: 650-845-6504	IC.	
DATE:	October 9, 2002		
NUMBER OF PAGES TO FOLLOW: 7 SENT BY: cas			
Re: Serial No. 09/768,080, Attorney Docket No. GC527C3			
Attachments: Transmittal Letter (1 page) in duplicate, and Response to Restriction Requirement (5 pages).			
The original of this facsimile will be sent to you via:			
Regular Mail Overnight Mail Hand Delivery Will Not Be Sent			
Please initial acknowledgment of receipt by return facsimile			

NOTE: The information contained in this facsimile message is confidential and may be subject to attorneyclient privilege and is intended only for the use of the above named individual(s). If you are not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, place notify us immediately by telephin (650/846-7517) and return the original transmission to us by mail.

FAX RECEIVED

OCT 1 : 2005

I hereby certify that this correspondence is being sent by facsimile transmission in accordance with § 1.6(d) addressed to Art Unit 1644, Before Final Facsimile No. (703) 872-9306, Commissioner for Patents, Washington, D.C. 20231 on the date shown below.

GROUP 1600

Date: October 9, 2002

Garol A. See

PATENT Docket No. GC527C3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of	
Estell et al.	Group Art Unit: 1644
Serial No.: 09/768,080) Examiner: Saunders, D.
Filed: January 23, 2001)
For: Proteins Producing an Altered Immunogenic Response and Methods of Making and Using the Same	/)))

TRANSMITTAL LETTER

Commissioner for Patents Washington, D.C. 20231

Sir:

In response to the Restriction Requirement dated September 27, 2002, enclosed please find the following document: Response to Restriction Requirement.

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16 and 1.17 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 07-1048 (Docket No. GC527C3). A duplicate of this paper is enclosed.

Respectfully submitted,

Date: October 9, 2002

Kamrin T. MacKnight Registration No. 38,230

Genencor International, Inc. 925 Page Mill Road Palo Alto, CA 94304-1013

Tel: 650-846-5838 Fax: 650-845-6504 I hereby certify that this correspondence is being sent by facsimile transmission in accordance with § 1.6(d)

addressed to Art Unit 1644, Before Final Facsimile No. (703) 872-9306, Commissioner for Patents, Washington, D.C. 20231 on the date shown below.

Date: October 9, 2002

Carol A. Soo

PATENT Docket No. GC527C3

Cotur.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Estell et al.

Serial No.: 09/768,080

Filed: January 23, 2001

For: Proteins Producing an Altered
Immunogenic Response and
Methods of Making and Using
the Same

Output

Description:

Head of Making and Using
The Same

Output

Description:

Descr

Group Art Unit: 1644

Examiner: Saunders, D.

RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents Washington, DC 20231

Sir:

In response to the Restriction Requirement dated September 27, 2002, Applicants respectfully request that the following amendments be made. A clean version of the rewritten, added, and/or cancelled claims with instructions for entry pursuant to 37 C.F.R. §1.121 (c)(1)(i) is included beginning on page 2 of this communication. A marked-up version of the rewritten, added, and/or cancelled claims pursuant to 37 C.F.R. §1.121 (c)(1)(ii) is attached as Appendix I. A clean version of the entire set of pending claims pursuant to 37 C.F.R. §1.121 (c)(3) as they would appear following entry of this amendment is attached as Appendix II. None of the amendments to the Claims is intended to narrow the scope of any of the amended Claims within the meaning of Festo¹.

¹ Festo Corp. v. Shoketsu Kogyo Kabushiki Co., No. 95-1066, 2000 WL 1753646 (Fed. Cir. Nov. 29, 2000).